297 related articles for article (PubMed ID: 15938721)
41. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations.
Bagg A
Hum Pathol; 2003 Apr; 34(4):352-8. PubMed ID: 12733115
[No Abstract] [Full Text] [Related]
42. [Chromosomal analysis, fluorescence in situ hybridization method, and spectral karyotyping in hematologic malignancies].
Nara N
Rinsho Byori; 2003 Jun; Suppl 126():124-30. PubMed ID: 12905952
[No Abstract] [Full Text] [Related]
43. [Molecular diagnosis and new gene engineering in hematological malignancies].
Funato T; Fujiwara J; Fujimaki S; Kaku M
Rinsho Byori; 2000 Oct; 48(10):887-91. PubMed ID: 11215098
[TBL] [Abstract][Full Text] [Related]
44. [Molecular detection of the BCR-ABL gen by RT-PCR in Costa Rican children with leukemia].
Jiménez-Arce G; Carrillo J; Chaves M; Jiménez R; Vargas M; Campos L; de la Guardia A; Valverde B
Rev Biol Trop; 2008 Dec; 56(4):1613-8. PubMed ID: 19419069
[TBL] [Abstract][Full Text] [Related]
45. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
[TBL] [Abstract][Full Text] [Related]
46. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
[TBL] [Abstract][Full Text] [Related]
47. [Genetic tests for leukemia].
Kitamura K
Rinsho Byori; 2002 Nov; Suppl 123():89-97. PubMed ID: 12652795
[TBL] [Abstract][Full Text] [Related]
48. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
49. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
50. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.
Li A; Goldwasser MA; Zhou J; Armstrong SA; Wang H; Dalton V; Fletcher JA; Sallan SE; Silverman LB; Gribben JG
Br J Haematol; 2005 Oct; 131(2):185-92. PubMed ID: 16197448
[TBL] [Abstract][Full Text] [Related]
51. Cytogenetics. An evolving role in the diagnosis and treatment of cancer.
Glassman AB
Clin Lab Med; 1997 Mar; 17(1):21-37. PubMed ID: 9138897
[TBL] [Abstract][Full Text] [Related]
52. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
53. Biotechnologies in haematological malignancies.
Foà R; Reato G; Guarini A
Forum (Genova); 1999; 9(3 Suppl 3):54-8. PubMed ID: 10607847
[TBL] [Abstract][Full Text] [Related]
54. The detection of minimal residual disease in acute lymphoblastic leukaemia.
Potter MN
Blood Rev; 1992 Jun; 6(2):68-82. PubMed ID: 1633509
[TBL] [Abstract][Full Text] [Related]
55. MicroRNAs in myeloid malignancies.
Gordon JE; Wong JJ; Rasko JE
Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
[TBL] [Abstract][Full Text] [Related]
56. Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature.
Hayne CC; Winer E; Williams T; Chaves F; Khorsand J; Mark HF
Exp Mol Pathol; 2006 Aug; 81(1):62-71. PubMed ID: 16765346
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic strategies to investigate cerebrospinal fluid involvement in haematological malignancies.
Galati D; Di Noto R; Del Vecchio L
Leuk Res; 2013 Mar; 37(3):231-7. PubMed ID: 23287431
[TBL] [Abstract][Full Text] [Related]
58. Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization.
Nebral K; König M; Schmidt HH; Lutz D; Sperr WR; Kalwak K; Brugger S; Dworzak MN; Haas OA; Strehl S
Haematologica; 2005 Jun; 90(6):746-52. PubMed ID: 15951287
[TBL] [Abstract][Full Text] [Related]
59. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
Kern W; Kohlmann A; Schoch C; Schnittger S; Haferlach T
Cancer; 2006 Nov; 107(10):2401-7. PubMed ID: 17041886
[TBL] [Abstract][Full Text] [Related]
60. Detection of early precursors of t(12;21) positive pediatric acute lymphoblastic leukemia during follow-up.
László R; Alpár D; Kajtár B; Lacza A; Ottóffy G; Kiss C; Bartyik K; Nagy K; Pajor L
Pediatr Blood Cancer; 2010 Jan; 54(1):158-60. PubMed ID: 19813247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
